Skip to content
PsychedeliaDokholyan Laboratory
Plate 382 of 545Verified

Lorcaserin

Also known aslorcaserine · LorcaserinA · lorcaserinum · A08AA11 · Lorcaserin [INN] · Belvig · AR-10A · T4U

(5R)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine

PubChem CID
11658860
Measurements
15
InChIKey
XTTZERNUQAFMOF-QMMMGPOBSA-N

I · Summary

What is known

Published passages, each quoted whole and attributed to the database that published it. Two blocks are written here rather than quoted, and both say so where they stand: the synthesized summary at the top, which may draw only on the passages beneath it, and the history note, which cites the works it came from. Every claim in either carries a marker to its source.

How it acts

  • Although the exact mechanism is unknown, it is believed to involve the selective activation of 5-HT2C receptors in the anorexigenic pro-opiomelanocortin neurons in the arcuate nucleus of the hypothalamus. This results in decreased food intake and satiety by promoting the release of alpha-melanocortin stimulating hormone, which acts on melanocortin-4 receptors.

    DrugBank

  • Lorcaserin is believed to decrease food consumption and promote satiety by selectively activating 5-HT2C receptors on anorexigenic pro-opiomelanocortin neurons located in the hypothalamus. The exact mechanism of action is not known.

    Hazardous Substances Data Bank (HSDB)US Natl Inst Health; DailyMed. Current Medication Information for BELVIQ (lorcaserin hydrochloride) tablets (August 2012). Available from, as of March 13, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7cbbb12f-760d-487d-b789-ae2d52a3e01f

Behavior carries the pharmacological classes and the acute-effect durations, with plasma half-life kept separate from duration of effect.

History, discovery and cultural use

— Not in this archive. PubChem, ChEMBL and the Human Protein Atlas publish pharmacology, regulation and toxicology, and none of them publishes a heading for when Lorcaserin was first made, by whom, or how it has been used. That is a gap in the databases this site reads and not a gap in the literature — the history of these compounds is written, at length and under peer review, in the works below. This site does not summarize them; it says where they are. Where a published passage above happens to touch origin or traditional use, it appears inside the entry that carries it.

Histories of this field

Scholarship on psychedelics generally, not on Lorcaserin specifically. Whether any of these treats this compound is a question for the book, not for this page.

  • Mescaline: A Global History of the First Psychedelic

    Traces mescaline and the peyote and San Pedro cacti from pre-Columbian ritual use through nineteenth-century chemistry to twentieth-century psychiatry and the counterculture.

    Jay M. Mescaline: A Global History of the First Psychedelic. Yale University Press, New Haven and London; 2019. ISBN 9780300231076.

  • Expanding Mindscapes: A Global History of Psychedelicsopen access

    Essays on the international and cross-cultural history of psychedelic science, deliberately decentring the standard North American and European account.

    Dyck E, Elcock C, editors. Expanding Mindscapes: A Global History of Psychedelics. The MIT Press, Cambridge MA; 2023. ISBN 9780262546935 (paper), 9780262376891 (open access). doi:10.7551/mitpress/14417.001.0001.

  • Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers

    Botany, ethnography and chemistry of the principal hallucinogenic plants, by the founder of modern ethnobotany and the chemist who first synthesized LSD.

    Schultes RE, Hofmann A, Rätsch C. Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers. 2nd ed. Healing Arts Press, Rochester VT; 2001. ISBN 9780892819799.

  • Psychonauts: Drugs and the Making of the Modern Mind

    The tradition of scientific self-experimentation with psychoactive drugs, and its part in the emergence of psychology and of modernism.

    Jay M. Psychonauts: Drugs and the Making of the Modern Mind. Yale University Press, New Haven; 2023. ISBN 9780300257946.

  • Ancient Psychoactive Substances

    Archaeological and bioarchaeological evidence for psychoactive plant use across the ancient world.

    Fitzpatrick SM, editor. Ancient Psychoactive Substances. University Press of Florida, Gainesville; 2018. ISBN 9780813056708.

  • History and Current Status of Psychedelics and Entactogens for the Treatment of Psychiatric Disorders

    A chapter tracing psychedelic and entactogen research from earlier ritual use through the mid-century research period to current clinical trials.

    Stroud C, Posey Norris SM, Matney C, editors. History and Current Status of Psychedelics and Entactogens for the Treatment of Psychiatric Disorders. In: Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. National Academies Press, Washington DC; 2022. NBK587225.

    Workshop proceedings record what participants said; they are not a consensus statement of the National Academies.

  • Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions

    Peer-reviewed review covering the isolation, synthesis, pharmacology and ritual use of peyote and mescaline.

    Dinis-Oliveira RJ, Pereira CL, da Silva DD. Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. Current Molecular Pharmacology 12(3):184–194; 2019. doi:10.2174/1874467211666181010154139.

Institutional archives

  • Heffter Research Institute Funds and coordinates clinical research on psilocybin, and keeps records of the studies it has supported since 1993. Sponsors the research it archives.
  • Multidisciplinary Association for Psychedelic Studies (MAPS) Sponsors clinical research, chiefly on MDMA-assisted therapy, and publishes an archive of historical and contemporary documents. A sponsor and an advocacy organization, not a disinterested archive; its clinical programme has a commercial arm.

The rest of this dossier

  • Affinity — 15 measurements in this archive, equilibrium constants kept apart from functional readouts.
  • Toxicology — nothing published for Lorcaserin. An absent record is an absence of study, not evidence of safety.
  • Systems — where this compound’s targets are transcribed, by brain region and tissue.

Passages via PubChem descriptive sections, aggregating DrugBank, LiverTox, FDA, DEA, HSDB, EPA. Each is quoted whole and attributed to the database that published it. The only prose written here about Lorcaserin is the history note, which says so on its face and carries a reference for every claim in it.

II · Identity

Structure and descriptors

Descriptors are computed here with RDKit from the structure PubChem returns — not from the archive's stored copy, so an edited local structure cannot reach this table.

2D structural depiction of lorcaserin
Depiction served by PubChem for CID 11658860. Not redrawn here, so the picture and the identity come from the same record.
Formula
C11H14ClNR
Molecular weight
195.69g/molR
Exact mass
195.0815DaR
cLogP
2.59R
TPSA
12.0ŲR
H-bond donors
1R
H-bond acceptors
1R
Rotatable bonds
0R
Aromatic rings
1R
Heavy atoms
13R
Fraction sp³
0.455R
Formal charge
0R

Computed with RDKit 2025.09.2 from the SMILES returned by PubChem. Audit run 26/09/2026.

Bemis–Murcko scaffold

c1ccc2c(c1)CCNCC2

No other compound in this archive shares it. All families

III · Behavior

Behavioral summary

Class, mechanism, and the duration of acute effects — each quoted from the record or trial that publishes it. Duration of effects and plasma half-life are shown separately, because they are different quantities and diverge by a factor of three or four.

Classification

MeSH indexes no pharmacological class for this compound.

Duration of acute subjective effects

—

No controlled human trial reporting a duration for this compound is cited here. The archive holds no other record of one either. A duration is not inferred from a chemical relative.

Plasma elimination half-life

How fast the body clears the drug — not how long the effects last. The two diverge sharply: LSD is cleared with a half-life of about 2.6 h while its subjective effects run 8–12 h.

  • The plasma half life is approximately 11 hours.

    DrugBank

Primary pharmacological drivers

ChEMBL holds no curated mechanism-of-action record for this compound. The measured affinities below are the evidence this archive has for what it binds.

Mechanism, as published

Quoted verbatim from the database named after each passage, never summarized.

  • In this study, /the researchers/ describe the in vitro and in vivo characteristics of lorcaserin ((1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3 benzazepine), a selective, high affinity 5-HT(2C) full agonist. Lorcaserin bound to human and rat 5-HT(2C) receptors with high affinity (K(i) = 15 +/- 1 nM, 29 +/- 7 nM, respectively), and it was…
    Hazardous Substances Data Bank (HSDB)PMID 18252809Thomsen WJ et al; J Pharmacol Exp Ther. 2008 May;325(2):577-87 (2008)
  • Although the exact mechanism is unknown, it is believed to involve the selective activation of 5-HT2C receptors in the anorexigenic pro-opiomelanocortin neurons in the arcuate nucleus of the hypothalamus. This results in decreased food intake and satiety by promoting the release of alpha-melanocortin stimulating hormone, which acts on mel…
    DrugBank
  • Lorcaserin is believed to decrease food consumption and promote satiety by selectively activating 5-HT2C receptors on anorexigenic pro-opiomelanocortin neurons located in the hypothalamus. The exact mechanism of action is not known.
    Hazardous Substances Data Bank (HSDB)US Natl Inst Health; DailyMed. Current Medication Information for BELVIQ (lorcaserin hydrochloride) tablets (August 2012). Available from, as of March 13, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7cbbb12f-760d-487d-b789-ae2d52a3e01f
  • Lorcaserin produced a dose-dependent weight loss over a 12-week period by promoting satiety and decreasing food consumption.
    DrugBank

IV · Clinical

Clinical description

Where this compound's substance class sits in ICD-11 and DSM-5-TR, and how much of the recorded literature speaks to each domain of a mental status examination.

No diagnostic chapter is shown for this compound. Either PubChem records no MeSH pharmacological class for it, or the class it records is not one of the substance classes ICD-11 gives a chapter to. Inferring a chapter from the compound’s name or its binding profile would be a diagnosis this archive is in no position to make.

How much has been written about each domain

The clinical domains, and how many of the records this archive holds for this compound say something under each. What the terms mean, and the word list behind every spoke, are set out in the method.

None of the 5 records this archive holds for this compound uses a term from any of the clinical domains. That is a statement about the literature recorded here, not about the compound.

V · Systems

Systems physiology

Where the targets this compound binds are transcribed — brain regions on the left, peripheral and autonomic tissues on the right. A join of two measurements, not a claim about what the compound does to either.

Brain

cerebral cortex — 18.2 nTPM, from HTR2A, HTR2C, HTR2Bcerebellum — 0.2 nTPM, from HTR2A, SLC6A4, HTR2Bhippocampal formation — 2.7 nTPM, from HTR2A, HTR2C, HTR2Bamygdala — 3.5 nTPM, from HTR2A, HTR2C, HTR2Bhypothalamus — 12.6 nTPM, from HTR2C, HTR2A, SLC6A4thalamus — no resolved target expressed herebasal ganglia — 28.2 nTPM, from HTR2C, HTR2A, HTR2Bmedulla oblongata — no resolved target expressed here

basal ganglia: drawn as the caudate nucleus, putamen and globus pallidus.

Measured but not drawn — this anatomogram has no outline for them: midbrain 2.2, spinal cord 1.0, retina 0.7, pituitary gland 0.4.

Body

heart — 4.6 nTPM, from HTR2B, SLC6A4, HTR2Asmooth muscle — 15.7 nTPM, from HTR2B, HTR2Alung — 27.2 nTPM, from SLC6A4, HTR2B, HTR2Aliver — 3.3 nTPM, from HTR2B, HTR2Akidney — 3.1 nTPM, from HTR2B, SLC6A4, HTR2Astomach — 4.4 nTPM, from HTR2B, SLC6A4, HTR2Aduodenum — 9.7 nTPM, from SLC6A4, HTR2B, HTR2Asmall intestine — 38.0 nTPM, from SLC6A4, HTR2B, HTR2Acolon — 8.5 nTPM, from HTR2B, HTR2A, SLC6A4adrenal gland — 17.2 nTPM, from HTR2B, HTR2A, SLC6A4thyroid gland — 3.2 nTPM, from HTR2B, SLC6A4, HTR2Apancreas — 1.3 nTPM, from SLC6A4, HTR2Burinary bladder — 2.0 nTPM, from HTR2B, HTR2Askeletal muscle — 0.3 nTPM, from HTR2A, HTR2Bspleen — 0.4 nTPM, from HTR2B, SLC6A4salivary gland — 0.6 nTPM, from SLC6A4, HTR2B, HTR2A
038 nTPM

Square-root ramp · shared scale across both plates

Shading is transcript level — not affinity, and not affinity combined with expression. Outlined but unshaded organs hold none of this compound’s resolved targets above the atlas’s detection threshold. Anatomy from EMBL-EBI Anatomogram (Apache License 2.0); regions identified by Uberon (uberon.org), CC BY 3.0.

Brain regions

Regions where this compound's measured targets are transcribed. Linked from the plate above.

  1. basal ganglia

    28.2 nTPM

  2. cerebral cortex

    18.2 nTPM

  3. hypothalamus

    12.6 nTPM

  4. amygdala

    3.5 nTPM

  5. hippocampal formation

    2.7 nTPM

  6. midbrain

    2.2 nTPM

  7. spinal cord

    1.0 nTPM

  8. retina

    0.7 nTPM

  9. pituitary gland

    0.4 nTPM

  10. cerebellum

    0.2 nTPM

Peripheral & autonomic

Tissues outside the CNS expressing the same targets — where a compound's bodily effects become possible.

  1. small intestine

    38.0 nTPM

  2. lung

    27.2 nTPM

  3. adrenal gland

    17.2 nTPM

  4. smooth muscle

    15.7 nTPM

  5. duodenum

    9.7 nTPM

  6. colon

    8.5 nTPM

  7. heart muscle

    4.6 nTPM

  8. stomach 1

    4.4 nTPM

  9. liver

    3.3 nTPM

  10. thyroid gland

    3.2 nTPM

  11. kidney

    3.1 nTPM

  12. urinary bladder

    2.0 nTPM

  13. pancreas

    1.3 nTPM

  14. salivary gland

    0.6 nTPM

  15. spleen

    0.4 nTPM

  16. skeletal muscle

    0.3 nTPM

Each row joins two published measurements and nothing else: the affinity this archive holds for the compound at that target, and the transcript level the Human Protein Atlas reports for that target’s gene in that region. Bars scale with expression only. Expression is not activation — a receptor transcribed in a region is a receptor available to be bound there, which is a weaker and more defensible claim than saying the region is affected.

Expression data from Human Protein Atlas (CC BY-SA 3.0), RNA expression, nTPM (normalized transcripts per million), consensus tissue dataset. Uhlén M, et al. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.

VI · Profile

Affinity rosette

The strongest measurement at each of 4 molecular targets. Cell-line and whole-organism screens are excluded here — they carry no affinity — and appear in the table below.

5-HT2A — Ki 8.89 pX5-HT2B — Ki 8.89 pX5-HT2C — Ki 7.82 pXSERT — Ki 5.58 pX5-HT2A5-HT2B5-HT2CSERT579
Fig. Radius is pX = −log₁₀(value in M), that is 9 − log₁₀(value in nM), computed from the normalized measurement. Hatched wedges are equilibrium binding constants (Ki, Kd); dashed outlines are functional readouts (IC₅₀, EC₅₀, AC₅₀, potency), which answer a different question and are not pooled with them. Rings mark whole pX units from 5 to 10, labeled every second ring in the gutter at the top. Where a target carries several measurements, the strongest is drawn.

VII · Toxicology

Toxicological profile

What has been measured, and what has been published — kept apart, and neither scored. There is no risk rating on this page; the archive once carried one, identical for every compound, produced by a stub.

Measured in this archive

Assays that bear on toxicity, drawn from the same ChEMBL records as everything else on this page. They are measurements of what a compound binds or does to cells — not verdicts about what it does to a person.

No hERG, cytochrome, cytotoxicity or transport measurement exists for Lorcaserin in this archive.

Published toxicology

— None. The toxicology databases this site reads — HSDB, RTECS and LiverTox, by way of PubChem — hold no record for Lorcaserin. They index compounds that have been studied for decades, so most of this archive has no entry. An absent record is an absence of study, not evidence of safety.

Published passages via PubChem toxicology sections, aggregating Hazardous Substances Data Bank (HSDB), RTECS, LiverTox. No figure on this page is scored, ranked or combined into a risk level.

VIII · Evidence

Every measurement

One row per published value. The identifier in the last column resolves to the ChEMBL assay record it was read from.

Equilibrium binding constants 13

Ki and Kd — a concentration at equilibrium. Directly comparable across rows at the same target.

TargetClassTypeValue (nM)pXOrganismAssay
5-HT2ASerotonin receptorsKi1.308.89Homo sapiensCHEMBL2340915
5-HT2BSerotonin receptorsKi1.308.89Homo sapiensCHEMBL2340914
5-HT2CSerotonin receptorsKi15.007.82Homo sapiensCHEMBL6185651
5-HT2CSerotonin receptorsKi15.007.82Homo sapiensCHEMBL2445936
5-HT2CSerotonin receptorsKi15.007.82Homo sapiensCHEMBL4309130
5-HT2ASerotonin receptorsKi98.507.01Homo sapiensCHEMBL4617358
5-HT2ASerotonin receptorsKi1126.95Homo sapiensCHEMBL4309131
5-HT2BSerotonin receptorsKi1746.76Homo sapiensCHEMBL4309132
5-HT2BSerotonin receptorsKi1896.72Homo sapiensCHEMBL958365
5-HT2BSerotonin receptorsKi2206.66Homo sapiensCHEMBL4617355
5-HT2CSerotonin receptorsKi2576.59Homo sapiensCHEMBL958366
SERTMonoamine transportersKi2,6065.58Homo sapiensCHEMBL958367
5-HT2ASerotonin receptorsKi2,7825.56Homo sapiensCHEMBL958364

Functional readouts 2

IC₅₀, EC₅₀, AC₅₀ and potency. Assay-dependent, and not interchangeable with a binding constant.

TargetClassTypeValue (nM)pXOrganismAssay
5-HT2CSerotonin receptorsEC509.008.05Homo sapiensCHEMBL2340916
5-HT2ASerotonin receptorsEC501,9205.72Homo sapiensCHEMBL4617356
P
PubChem
C
ChEMBL
R
Computed here with RDKit
D
Derived here from the stored measurement

IX · Trials

Registered clinical trials

Studies filed with ClinicalTrials.gov that name this compound as an intervention. A registered trial is a protocol, not a result — status and enrollment are printed beside every row, and withdrawn studies are counted rather than hidden.

46T

Registered studies

1T

Open or ongoing

44T

With a phase recorded

By phase

A study may carry two phase codes at once, so these count studies bearing each phase and do not sum to the total.

  • Early phase 11
  • Phase 121
  • Phase 213
  • Phase 38
  • Phase 46
  • Not applicable1

By status

The registry’s own status for each record. Withdrawn and terminated studies are counted here rather than hidden — a stopped trial is part of what is known.

  • Completed27
  • Terminated12
  • Unknown status3
  • Withdrawn2
  • Active, not recruiting1
  • Available1

The 25 most recently started, of 46

Newest first by start date. Each identifier opens the registry record it came from; the title is the sponsor’s own, quoted.

  • NCT04205071Withdrawn · Phase 1

    Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer

    Enrollment
    0Tactual
    Started
    2020-11-01
    Sponsor
    Ohio State University Comprehensive Cancer Center

    Conditions Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage IA Breast Cancer AJCC v8 · Anatomic Stage IB Breast Cancer AJCC v8 · Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage IIA Breast Cancer AJCC v8 · Anatomic Stage IIB Breast Cancer AJCC v8 and 18 more

    Matched “lorcaserin” in the study’s intervention “Lorcaserin”

  • NCT04572243Terminated · Phase 3

    A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

    Enrollment
    22Tactual
    Started
    2020-09-23
    Sponsor
    Eisai Inc.

    Conditions Epilepsies, Myoclonic

    Matched “lorcaserin” in the study’s intervention “Lorcaserin”

  • NCT04396834Terminated · Phase 2

    Mechanisms of Lorcaserin for Smoking Cessation

    Enrollment
    3Tactual
    Started
    2019-12-04
    Sponsor
    The Mind Research Network

    Conditions Tobacco Use Disorder · Smoking Cessation

    Matched “lorcaserin” in the study’s intervention “Lorcaserin Oral Tablet”

  • NCT04396847Terminated · Phase 2

    Laboratory Screening of Lorcaserin for Alcohol Use Disorder

    Enrollment
    5Tactual
    Started
    2019-10-25
    Sponsor
    The Mind Research Network

    Conditions Alcohol Use Disorder · Tobacco Smoking

    Matched “lorcaserin” in the study’s intervention “Lorcaserin Oral Tablet”

  • NCT03720574Terminated · Phase 3

    Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients

    Enrollment
    100Tactual
    Started
    2019-09-17
    Sponsor
    Kanion & Huawe Medicine Co.,Ltd

    Conditions Obesity

    Matched “lorcaserin” in the study’s intervention “Lorcaserin 10 mg BID”

  • NCT03637842Terminated · Early phase 1

    Lorcaserin for Cannabis Use Disorder

    Enrollment
    5Tactual
    Started
    2019-08-01
    Sponsor
    New York State Psychiatric Institute

    Conditions Cannabis Use Disorder

    Matched “lorcaserin” in the study’s intervention “Lorcaserin”

  • NCT03812523Unknown status · Phase 2

    Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

    Enrollment
    50Testimated
    Started
    2019-06
    Sponsor
    Southeastern Regional Medical Center

    Conditions Chemotherapy-Induced Peripheral Neuropathy

    Matched “lorcaserin” in the study’s intervention “Lorcaserin”

  • NCT03266939Withdrawn · Phase 1

    Rebalancing the Serotonergic System in Cocaine Dependence

    Enrollment
    0Tactual
    Started
    2018-10-04
    Sponsor
    Mclean Hospital

    Conditions Cocaine Dependence

    Matched “lorcaserin” in the study’s intervention “Lorcaserin”

  • NCT03627936Completed · Phase 1

    A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants

    Enrollment
    40Tactual
    Started
    2018-08-07
    Sponsor
    Eisai Inc.

    Conditions Healthy Participants

    Matched “lorcaserin” in the study’s intervention “Lorcaserin manufactured at Zofingen”

  • NCT03011645Terminated · Phase 1

    Gene-by-Stress Interactions in Intervention Studies Significance

    Enrollment
    7Tactual
    Started
    2018-05-24
    Sponsor
    Duke University

    Conditions Cardiovascular Diseases

    Matched “lorcaserin” in the study’s intervention “Lorcaserin”

  • NCT03192995Terminated · Phase 2

    Treatment With Lorcaserin for Cocaine Use: The TLC Study

    Enrollment
    22Tactual
    Started
    2018-01-01
    Sponsor
    Glenn-Milo Santos

    Conditions Cocaine Use Disorder

    Matched “lorcaserin” in the study’s intervention “lorcaserin”

  • NCT03007394Completed · Phase 2

    Lorcaserin in the Treatment of Cocaine Use Disorder

    Enrollment
    272Tactual
    Started
    2017-12-19
    Sponsor
    National Institute on Drug Abuse (NIDA)

    Conditions Cocaine-Related Disorders

    Matched “lorcaserin” in the study’s intervention “Lorcaserin”

  • NCT03338296Terminated · Phase 4

    Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years

    Enrollment
    278Tactual
    Started
    2017-09-28
    Sponsor
    Eisai Inc.

    Conditions Obesity

    Matched “lorcaserin” in the study’s intervention “lorcaserin hydrochloride XR”

  • NCT03253926Completed · Phase 1 / Phase 2

    Effect of Lorcaserin on Cannabis Withdrawal and Self-administration

    Enrollment
    15Tactual
    Started
    2017-09-05
    Sponsor
    New York State Psychiatric Institute

    Conditions Cannabis Use

    Matched “lorcaserin” in the study’s intervention “Lorcaserin”

  • NCT03169816Completed · Phase 2 / Phase 3

    Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder

    Enrollment
    60Tactual
    Started
    2017-05-25
    Sponsor
    New York State Psychiatric Institute

    Conditions Opioid-use Disorder

    Matched “lorcaserin” in the study’s intervention “Lorcaserin”

  • NCT03552107Completed

    Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic

    Enrollment
    157Tactual
    Started
    2017-04-11
    Sponsor
    Scripps Whittier Diabetes Institute

    Conditions Obesity · Weight Loss · Overweight

    Matched “lorcaserin” in the study’s intervention “Lorcaserin”

  • NCT03143855Completed · Phase 1

    Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder

    Enrollment
    32Tactual
    Started
    2017-01-30
    Sponsor
    Virginia Commonwealth University

    Conditions Opioid Abuse · Opioid Dependence · Opioid-Related Disorders · Opioid Use

    Matched “lorcaserin” in the study’s intervention “Lorcaserin”

  • NCT02906644Completed · Phase 2

    Combination Nicotine Patch / Lorcaserin for Smoking Cessation

    Enrollment
    97Tactual
    Started
    2016-11-08
    Sponsor
    Duke University

    Conditions Nicotine Dependence

    Matched “lorcaserin” in the study’s intervention “lorcaserin”

  • NCT02932215Completed · Phase 1

    Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder

    Enrollment
    17Tactual
    Started
    2016-10
    Sponsor
    New York State Psychiatric Institute

    Conditions Cannabis Use Disorder

    Matched “lorcaserin” in the study’s intervention “lorcaserin”

  • NCT02796144Terminated · Phase 4

    MEtformin and Lorcaserin for WeighT Loss in Schizophrenia

    Enrollment
    71Tactual
    Started
    2016-09
    Sponsor
    University of North Carolina, Chapel Hill

    Conditions Schizophrenia · Schizoaffective Disorder · Overweight

    Matched “lorcaserin” in the study’s intervention “Lorcaserin”

  • NCT02412631Terminated · Phase 2 / Phase 3

    Addressing Post Cessation Weight Gain

    Enrollment
    84Tactual
    Started
    2016-06-15
    Sponsor
    Mayo Clinic

    Conditions Obesity · Smoking Cessation

    Matched “lorcaserin” in the study’s intervention “lorcaserin”

  • NCT02523690Terminated · Phase 1 / Phase 2

    Evaluating Muscle Weakness Improvement With Lorcaserin in ICU

    Enrollment
    5Tactual
    Started
    2015-12
    Sponsor
    Johns Hopkins University

    Conditions Muscle Weakness · Sepsis

    Matched “lorcaserin” in the study’s intervention “Lorcaserin”

  • NCT02680288Unknown status · Phase 1 / Phase 2

    Lorcaserin Intra Venous Cocaine Effects

    Enrollment
    32Testimated
    Started
    2015-11
    Sponsor
    Midwest Biomedical Research

    Conditions Cocaine Use Disorders

    Matched “lorcaserin” in the study’s intervention “Lorcaserin, 10 mg”

  • NCT02537873Completed · Phase 1

    Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder

    Enrollment
    29Tactual
    Started
    2015-07
    Sponsor
    Virginia Commonwealth University

    Conditions Cocaine Use Disorder

    Matched “lorcaserin” in the study’s intervention “Lorcaserin”

  • NCT03143543Terminated · Phase 1

    Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder

    Enrollment
    171Tactual
    Started
    2015-07
    Sponsor
    Virginia Commonwealth University

    Conditions Cocaine-Related Disorders · Opioid-Related Disorders

    Matched “lorcaserin” in the study’s intervention “Group A Lorcaserin (10mg)”

Records from ClinicalTrials.gov (U.S. National Library of Medicine, NIH), API v2. A study is listed against a compound only when a verified name for that compound appears as a whole word in one of the study's own intervention names. A short code must appear as written, and a name the registry uses for something else (Aleph, a vaccine maker) is not matched. Title matches are not accepted. The matched name and the intervention text it matched are shown with every row.

Searched as lorcaserin · lorcaserine · LorcaserinA. Run this search at the registry — it returns the unfiltered result, including studies this page rejected as belonging to a different molecule.

A registered trial is a protocol somebody filed with the registry. It is not a result, and nothing on this plate says whether Lorcaserin worked.

XI · Literature

Sources behind this dossier

The papers this compound's values were read from, ranked by what each contributed. Not a review of the field.

Every paper below is one some value on this page came from — a binding constant, a passage of pharmacology or toxicology, or a measured duration. Each entry says what this archive took from it. Nothing else is claimed about any of them: the title is the study’s own account of itself, and a summary written here would be an assertion with no source behind it.

  1. 01

    Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization

    Thomsen WJ, Grottick AJ, Menzaghi F et al. · The Journal of pharmacology and experimental therapeutics 2008

    • · Mechanism of Action

    PMID 18252809